Research has shown that targeting KRAS driver mutations with high-fidelity Cas9 can restrain lung cancer in preclinical models. This approach may have implications for cancer therapy, potentially overcoming drug resistance and enhancing precision medicine. The method involves gene editing, which could lead to more precise treatment options.